Pepaxto (melphalan flufenamide) with dexamethasone gained accelerated approval in February 2021, but the therapy failed a confirmatory trial. The manufacturer, Oncopeptides, then suspended enrollment. In July 2021, the FDA said there was a “detrimental effect on overall survival” in the study.
About a year later, an agency committee voted 14-2 in concluding an unsafe benefit-risk ratio. In August 2023, the FDA proposed pulling the approval, and the decision was finalized Feb. 23.
In a news release, the agency said “it is FDA’s understanding that Oncopeptides does not currently market Pepaxto in the U.S.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
